Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis

Oncogenic RAS is a critical driver for the initiation and progression of several types of cancers. However, effective therapeutic strategies by targeting RAS, in particular RAS(G12D) and RAS(G12V), and associated downstream pathways have been so far unsuccessful. Treatment of oncogenic RAS-ravaged c...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Muyun, Wang, Dan, Luo, Yongde, Hu, Lianghao, Bi, Yawei, Ji, Juntao, Huang, Haojie, Wang, Guoqiang, Zhu, Liang, Ma, Jianjia, Kim, Eunice, Luo, Catherine K., Abbruzzese, James L., Li, Xiaokun, Yang, Vincent W., Li, Zhaoshen, Lu, Weiqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887267/
https://www.ncbi.nlm.nih.gov/pubmed/33594044
http://dx.doi.org/10.1038/s41419-021-03473-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7887267/
https://www.ncbi.nlm.nih.gov/pubmed/33594044
http://dx.doi.org/10.1038/s41419-021-03473-6

Ejemplares similares